EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax

Jamese J Hilliard, Charles Jakielaszek iD, Frank Mannino, Mohammad Hossain, Lian Qian, Cindy Fishman iD, Samandra Demons, Jeremy Hershfield, Carl Soffler, Riccardo Russo, Lisa Henning, Joseph Novak und 1 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01497-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jamese J Hilliard und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anthrax, Bacillus anthracis, Anthrax Vaccines, Acenaphthenes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DOD | Defense Threat Reduction Agency (DTRA), GlaxoSmithKline (GSK).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacillus anthracis is a Gram-positive Centers for Disease Control and Prevention category “A” biothreat pathogen. Without early treatment, inhalation of anthrax spores with progression to inhalational anthrax disease is associated with high fatality rates. Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is being evaluated for use against biothreat and conventional pathogens. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode and has in vitro activity against a collection of B. anthracis isolates including antibacterial-resistant strains, with the MIC 90 ranging from 0.5 to 1 µg/mL. In vivo activity of gepotidacin was also evaluated in the New Zealand White rabbit model of inhalational anthrax. The primary endpoint was survival, with survival duration and bacterial clearance as secondary endpoints. The trigger for treatment was the presence of anthrax protective antigen in serum. New Zealand White rabbits were dosed intravenously for 5 days with saline or gepotidacin at 114 mg/kg/d to simulate a dosing regimen of 1,000 mg intravenous (i.v.) three times a day (TID) in humans. Gepotidacin provided a survival benefit compared to saline control, with 91% survival ( P -value: 0.0001). All control animals succumbed to anthrax and were found to be blood- and organ culture-positive for B. anthracis . The novel mode of action, in vitro microbiology, preclinical safety, and animal model efficacy data, which were generated in line with Food and Drug Administration Animal Rule, support gepotidacin as a potential treatment for anthrax in an emergency biothreat situation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraxBacillus anthracisAnthrax VaccinesAcenaphthenesHeterocyclic Compounds, 3-RingRespiratory Tract InfectionsRabbitsHumansAnimalsAnti-Bacterial AgentsDisease Models, Animal

Stichwörter der Autor:innen

Bacillus anthracisFDA Animal Rulebiothreatgepotidacin

Substanzen

gepotidacinAnti-Bacterial AgentsAnthrax VaccinesAcenaphthenesHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • GSK, Collegeville, Pennsylvania, USA.
  • US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
  • Rutgers University School of Medicine, Newark, New Jersey, USA.
  • Battelle Biomedical Research Center (BBRC), Columbus, Ohio, USA.

ORCID-Profile: Charles Jakielaszek, Cindy Fishman, Karen O'Dwyer

Förderung

  • DOD | Defense Threat Reduction Agency (DTRA)
  • GlaxoSmithKline (GSK)

Zitieren

APA

Hilliard, J. J., Jakielaszek, C., Mannino, F., Hossain, M., Qian, L., Fishman, C., Demons, S., Hershfield, J., Soffler, C., Russo, R., Henning, L., Novak, J., & O'Dwyer, K. (2024). Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01497-23

Vancouver

Hilliard JJ, Jakielaszek C, Mannino F, Hossain M, Qian L, Fishman C, et al. Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01497-23

BibTeX
@article{Hilliard2024,
  author = {Hilliard, Jamese J and Jakielaszek, Charles and Mannino, Frank and Hossain, Mohammad and Qian, Lian and Fishman, Cindy and Demons, Samandra and Hershfield, Jeremy and Soffler, Carl and Russo, Riccardo and Henning, Lisa and Novak, Joseph and O'Dwyer, Karen},
  title = {Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01497-23}
}
Kostenlos starten →